---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055645"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:23:11.817635+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics Q1 net loss $11.1M; cash $270.7M; advancing DT-216P2, DT-168, HD, DM1 programs

## Summary
- Net loss of $11.1M for Q1 2024; R&D expenses $9.8M, G&A expenses $4.6M.
- Cash and securities $270.7M as of March 31, 2024; expected funding into 2029.
- DT-216P2 for Friedreich Ataxia: GLP studies by year-end 2024; patient trials start 2025.
- DT-168 for FECD: Phase 1 development expected to start in 2024; observational study enrolling 200 patients.
- GeneTAC pipeline: HD and DM1 programs advancing toward development candidates; preclinical data showed mutant gene knockdown.

## SEC filing metadata
- accession: 0000950170-24-055645
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017024055645/0000950170-24-055645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017024055645/dsgn-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055645
- JSON: https://secwatch.observer/filing/0000950170-24-055645.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055645.txt

## Key facts
- Earnings Releases
  Design Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $11.1 million.
  - Period: the quarter ended March 31, 2024
  - Net income: $11.1 million
  - Result: reported results
  source text: Net loss was $11.1 million for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000095017024055645/0000950170-24-055645-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.